About Venus MedTech
Venus MedTech is a company based in Hangzhou (China) founded in 2009 by Eric Zi.. Venus MedTech has raised $37 million across 5 funding rounds from investors including Qiming Venture Partners, DCP and Goldman Sachs Investment Partners. The company has 691 employees as of December 31, 2024. Venus MedTech has completed 5 acquisitions, including InterValve, Keystone Heart and Transcatheter Technologies. Venus MedTech operates in a competitive market with competitors including Shockwave Medical, Cardiac Dimensions, Pi-Cardia, Symetis and Peijia Medical Technologies, among others.
- Headquarter Hangzhou, China
- Employees 691 as on 31 Dec, 2024
- Founders Eric Zi
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Venus Medtech (Hangzhou), Inc. Class H
-
Annual Revenue
$65.73 M (USD)-5.98as on Dec 31, 2024
-
Net Profit
$-99.72 M (USD)0.41as on Dec 31, 2024
-
EBITDA
$-38.37 M (USD)41.75as on Dec 31, 2024
-
Total Equity Funding
$37 M (USD)
in 5 rounds
-
Latest Funding Round
-
Investors
Qiming Venture Partners
& 3 more
-
Employee Count
691
as on Dec 31, 2024
-
Investments & Acquisitions
InterValve
& 4 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Venus MedTech
Venus MedTech is a publicly listed company on the HKEX with ticker symbol 2500 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Venus MedTech
Venus MedTech has successfully raised a total of $37M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Last Round
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2018 | Amount | Private Equity Round - Venus MedTech | Valuation |
investors |
|
| May, 2018 | Amount | Series C - Venus MedTech | Valuation | DCP |
|
| Mar, 2016 | Amount | Series C - Venus MedTech | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Venus MedTech
Venus MedTech has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Qiming Venture Partners, DCP and Goldman Sachs Investment Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are managed across multiple sectors by DCP.
|
Founded Year | Domain | Location | |
|
DNV Capital is engaged in asset management for healthcare and technology industries.
|
Founded Year | Domain | Location | |
|
Venture capital investments are directed toward multiple sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Venus MedTech
Venus MedTech has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include InterValve, Keystone Heart and Transcatheter Technologies. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of a novel transcatheter valve replacement system for mitral and tricuspid valve replacement. This system is designed for transfemoral delivery, avoiding open-heart surgery. Key features include a short profile to minimize ventricular protrusion and reduce LVOT obstruction risk, a robust anchoring mechanism, and an enhanced sealing solution to prevent paravalvular leaks. The device is currently limited to investigational use.
|
2011 | ||||
|
Implantable devices for heart valve repair and replacement
|
2009 | ||||
|
Catheter-based heart valve implantation and aortic therapy systems are developed.
|
2009 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Venus MedTech
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Venus Medtech Comparisons
Competitors of Venus MedTech
Venus MedTech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Shockwave Medical, Cardiac Dimensions, Pi-Cardia, Symetis and Peijia Medical Technologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cardiovascular balloon dilation catheters with lithotripsy electrodes are developed.
|
|
| domain | founded_year | HQ Location |
Invasive cardiac implants for heart failure treatment are developed.
|
|
| domain | founded_year | HQ Location |
Non-implant devices for cardiac valve repair are developed and manufactured.
|
|
| domain | founded_year | HQ Location |
Minimally invasive heart valve replacement devices are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Medical devices for cardiac and cerebrovascular treatments are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Venus Medtech
Frequently Asked Questions about Venus MedTech
When was Venus MedTech founded?
Venus MedTech was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Where is Venus MedTech located?
Venus MedTech is headquartered in Hangzhou, China. It is registered at Hangzhou, Zhejiang, China.
Who is the current CEO of Venus MedTech?
Eric Zi is the current CEO of Venus MedTech. They have also founded this company.
Is Venus MedTech a funded company?
Venus MedTech is a funded company, having raised a total of $37M across 5 funding rounds to date. The company's 1st funding round was a Series C of $37M, raised on Apr 06, 2012.
How many employees does Venus MedTech have?
As of Dec 31, 2024, the latest employee count at Venus MedTech is 691.
What is the annual revenue of Venus MedTech?
Annual revenue of Venus MedTech is $65.73M as on Dec 31, 2024.
What does Venus MedTech do?
Venus MedTech is a developer of medical products used during cardiovascular surgeries. Venus Medtech develops and manufactures an advanced interventional artificial cardiac valve system. Additionally, its products include artificial aorta, pulmonary artery, conveying system, compression loading system, etc. Has applied for multiple patents. As of July 2016, Its transcatheter aortic valves have completed clinical trials and follow-up and are pending China Food and Drug Administration (CFDA) clearance, and its transcatheter pulmonic valves are completing it clinical trials. Both of the valves are expected to be the first transcatheter valves approved in China. They are also developing the next-generation heart valves with pre-crimping technology. In 2016, -Transcatheter Technologies a medical device company that has developed a full range of transcatheter valve implantation systems for catheter-based heart valve therapy, announced that it had sold its technology portfolio to Venus Medtech.
Who are the top competitors of Venus MedTech?
Venus MedTech's top competitors include Shockwave Medical, Cardiac Dimensions and JenaValve Technology.
Is Venus MedTech publicly traded?
Yes, Venus MedTech is publicly traded on HKEX under the ticker symbol 2500.
How many acquisitions has Venus MedTech made?
Venus MedTech has made 5 acquisitions, including InterValve, Keystone Heart, and Transcatheter Technologies.
Who are Venus MedTech's investors?
Venus MedTech has 4 investors. Key investors include Qiming Venture Partners, DCP, Goldman Sachs Investment Partners, and DNV Capital.
What is Venus MedTech's ticker symbol?
The ticker symbol of Venus MedTech is 2500 on HKEX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.